Nanoparticle Delivery of Immunostimulatory Alu RNA for Cancer Immunotherapy

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2023 Sep 11

PMID 37691856

Authors

Kyle M Garland

Alexander J Kwiatkowski

John T Tossberg

Philip S Crooke 3rd

Thomas M Aune

John T Wilson

Affiliations

Soon will be listed here.

Abstract

Significance: Loss of A-to-I editing leads to accumulation of unedited Alu RNAs that activate innate immunity via RNA-sensing pattern recognition receptors. When packaged into endosome-releasing polymer nanoparticles, AluJB RNA becomes highly immunostimulatory and can be used pharmacologically to inhibit tumor growth in mouse melanoma models. These findings identify Alu RNAs as a new class of nucleic acid innate immune agonists for cancer immunotherapy.

Citing Articles

Advances in A-to-I RNA editing in cancer.

Zhang Y, Li L, Mendoza J, Wang D, Yan Q, Shi L Mol Cancer. 2024; 23(1):280.

PMID: 39731127 PMC: 11673720. DOI: 10.1186/s12943-024-02194-6.

Inverted Alu repeats: friends or foes in the human transcriptome.

Lee K, Ku J, Ku D, Kim Y Exp Mol Med. 2024; 56(6):1250-1262.

PMID: 38871814 PMC: 11263572. DOI: 10.1038/s12276-024-01177-3.

References

Roers A, Hiller B, Hornung V . Recognition of Endogenous Nucleic Acids by the Innate Immune System. Immunity. 2016; 44(4):739-54. DOI: 10.1016/j.immuni.2016.04.002. View

McWhirter S, Jefferies C . Nucleic Acid Sensors as Therapeutic Targets for Human Disease. Immunity. 2020; 53(1):78-97. DOI: 10.1016/j.immuni.2020.04.004. View

Uehata T, Takeuchi O . RNA Recognition and Immunity-Innate Immune Sensing and Its Posttranscriptional Regulation Mechanisms. Cells. 2020; 9(7). PMC: 7407594. DOI: 10.3390/cells9071701. View

Schlee M, Hartmann G . Discriminating self from non-self in nucleic acid sensing. Nat Rev Immunol. 2016; 16(9):566-80. PMC: 7097691. DOI: 10.1038/nri.2016.78. View

Convertine A, Benoit D, Duvall C, Hoffman A, Stayton P . Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release. 2008; 133(3):221-9. PMC: 3110267. DOI: 10.1016/j.jconrel.2008.10.004. View

Vanpouille-Box C, Hoffmann J, Galluzzi L . Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2019; 18(11):845-867. DOI: 10.1038/s41573-019-0043-2. View

Elion D, Cook R . Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget. 2018; 9(48):29007-29017. PMC: 6034747. DOI: 10.18632/oncotarget.25626. View

Baker A, Slack F . ADAR1 and its implications in cancer development and treatment. Trends Genet. 2022; 38(8):821-830. PMC: 9283316. DOI: 10.1016/j.tig.2022.03.013. View

Bourquin C, Pommier A, Hotz C . Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. Pharmacol Res. 2019; 154:104192. DOI: 10.1016/j.phrs.2019.03.001. View

10.

Convertine A, Diab C, Prieve M, Paschal A, Hoffman A, Johnson P . pH-responsive polymeric micelle carriers for siRNA drugs. Biomacromolecules. 2010; 11(11):2904-11. PMC: 3026907. DOI: 10.1021/bm100652w. View

11.

Shae D, Becker K, Christov P, Yun D, Lytton-Jean A, Sevimli S . Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019; 14(3):269-278. PMC: 6402974. DOI: 10.1038/s41565-018-0342-5. View

12.

Heinrich M, Purcell C, Pruijssers A, Zhao Y, Spurlock 3rd C, Sriram S . Endogenous double-stranded Alu RNA elements stimulate IFN-responses in relapsing remitting multiple sclerosis. J Autoimmun. 2019; 100:40-51. PMC: 6513682. DOI: 10.1016/j.jaut.2019.02.003. View

13.

Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View

14.

Garland K, Sevimli S, Kilchrist K, Duvall C, Cook R, Wilson J . Microparticle Depots for Controlled and Sustained Release of Endosomolytic Nanoparticles. Cell Mol Bioeng. 2019; 12(5):429-442. PMC: 6816657. DOI: 10.1007/s12195-019-00571-6. View

15.

Carson C, Becker K, Garland K, Pagendarm H, Stone P, Arora K . A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA. J Control Release. 2022; 345:354-370. PMC: 9133199. DOI: 10.1016/j.jconrel.2022.03.020. View

16.

Hammerich L, Marron T, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S . Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019; 25(5):814-824. DOI: 10.1038/s41591-019-0410-x. View

17.

Chow K, Gale Jr M, Loo Y . RIG-I and Other RNA Sensors in Antiviral Immunity. Annu Rev Immunol. 2018; 36:667-694. DOI: 10.1146/annurev-immunol-042617-053309. View

18.

Knight F, Gilchuk P, Kumar A, Becker K, Sevimli S, Jacobson M . Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8 Lung-Resident Memory T Cells. ACS Nano. 2019; 13(10):10939-10960. PMC: 6832804. DOI: 10.1021/acsnano.9b00326. View

19.

Zitvogel L, Galluzzi L, Kepp O, Smyth M, Kroemer G . Type I interferons in anticancer immunity. Nat Rev Immunol. 2015; 15(7):405-14. DOI: 10.1038/nri3845. View

20.

Jacobson M, Wang-Bishop L, Becker K, Wilson J . Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy. Biomater Sci. 2018; 7(2):547-559. DOI: 10.1039/c8bm01064a. View